Omics and multi-omics analysis for the early identification and improved outcome of patients with psoriatic arthritis

Gurke, R. et al. (2022) Omics and multi-omics analysis for the early identification and improved outcome of patients with psoriatic arthritis. Biomedicines, 10(10), 2387. (doi: 10.3390/biomedicines10102387) (PMID:36289648) (PMCID:PMC9598654)

Abstract

The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients.

• Item Type: Articles
• Additional Information: HIPPOCRATES has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no. 101007757. The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA.
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Whitfield, Mr Phil and Goodyear, Professor Carl
• Authors: Gurke, R., Bendes, A., Bowes, J., Koehm, M., Twyman, R. M., Barton, A., Elewaut, D., Goodyear, C., Hahnefeld, L., Hillenbrand, R., Hunter, E., Ibberson, M., Ioannidis, V., Kugler, S., Lories, R. J., Resch, E., Rüping, S., Scholich, K., Schwenk, J. M., Waddington, J. C., Whitfield, P., Geisslinger, G., FitzGerald, O., Behrens, F., and Pennington, S. R.
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Research Centre: College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology
• Journal Name: Biomedicines
• Publisher: MDPI
• ISSN: 2227-9059
• ISSN (Online): 2227-9059
• Published Online: 24 September 2022
• Copyright Holders: Copyright © 2022 The Authors
• First Published: First published in Biomedicines 10(10): 2387
• Publisher Policy: Reproduced under a Creative Commons License